Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | Director | June 30, 2023 | July 03, 2023 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Accounting Officer | July 28, 2026 | July 31, 2026 |
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bio Green Med Solution, Inc.
Report date June 30, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,602 |
Reported balance
After 2023-06-30 transaction · row 1
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 21,219 · Balance 40,602 F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-06-30 | Direct | 42,438 |
Reported balance
After 2023-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-30 · Grant · Acquired 42,438 · Balance 42,438 F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024.
F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 10,000 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 15,000 · Balance 25,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 15,000 · Balance 10,000 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 15,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 25,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 25,000 RSUs reported in Table I (10,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 25,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 25,000 RSUs reported in Table I (10,000 RSUs) are subject to vesting.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2023 Filed Mar 23, 2023 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001140361-23-013190 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001567619-23-005293 · doc1.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,481 Underlying: Ordinary Shares · 20,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 10,569 | $48.66 | $514,331.93 |
DisclosureSEC source: 0001567619-23-005293 · doc1.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $48.43 to $49.06, inclusive. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 9,431 | $48.14 | $454,014.00 |
DisclosureSEC source: 0001567619-23-005293 · doc1.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,569 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $47.43 to $48.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 20,000 | $15.04 | $300,800.00 |
DisclosureSEC source: 0001567619-23-005293 · doc1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $52.97 | $0.00 |
DisclosureSEC source: 0001140361-23-010180 · form4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Ordinary Shares · 38,000 shares Expires 2033-03-02 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 2, 2024 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 18, 2022 Filed Nov 19, 2022 02:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001567619-22-020647 · doc1.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,481 Underlying: Ordinary Shares · 10,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 18, 2022 Filed Nov 19, 2022 02:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 226 | $58.27 | $13,170.04 |
DisclosureSEC source: 0001567619-22-020647 · doc1.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $57.415 to $58.29, inclusive. Read SEC document |
| November 18, 2022 Filed Nov 19, 2022 02:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 9,774 | $57.04 | $557,539.26 |
DisclosureSEC source: 0001567619-22-020647 · doc1.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $56.39 to $57.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| November 18, 2022 Filed Nov 19, 2022 02:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $15.04 | $150,400.00 |
DisclosureSEC source: 0001567619-22-020647 · doc1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001567619-22-018818 · doc1.xml · derivative · entry 6 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,481 Underlying: Ordinary Shares · 20,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,164 | $58.98 | $68,653.42 |
DisclosureSEC source: 0001567619-22-018818 · doc1.xml · nonDerivative · entry 5 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $58.88 to $59.085, inclusive. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,785 | $58.25 | $220,489.12 |
DisclosureSEC source: 0001567619-22-018818 · doc1.xml · nonDerivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,164 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $57.865 to $58.81, inclusive. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 7,144 | $57.34 | $409,602.67 |
DisclosureSEC source: 0001567619-22-018818 · doc1.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,949 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $56.86 to $57.85, inclusive. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 7,907 | $56.39 | $445,867.82 |
DisclosureSEC source: 0001567619-22-018818 · doc1.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,093 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $55.855 to $56.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 20,000 | $15.04 | $300,800.00 |
DisclosureSEC source: 0001567619-22-018818 · doc1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:13 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 31,645 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071903 · tm2218645-6_4seq1.xml · derivative · entry 2 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:13 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 15,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071903 · tm2218645-6_4seq1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,383 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $32.45 | $0.00 |
DisclosureSEC source: 0001140361-22-006898 · form4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Ordinary Shares · 45,500 shares Expires 2032-02-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 23, 2023 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 23, 2021 Filed Nov 27, 2021 02:19 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 4,519 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001567619-21-021197 · doc1.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,481 Underlying: Ordinary Shares · 4,519 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 23, 2021 Filed Nov 27, 2021 02:19 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,819 | $58.43 | $106,285.99 |
DisclosureSEC source: 0001567619-21-021197 · doc1.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $58.10 to $58.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 23, 2021 Filed Nov 27, 2021 02:19 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,700 | $57.51 | $155,286.99 |
DisclosureSEC source: 0001567619-21-021197 · doc1.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $56.97 to $57.95, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 23, 2021 Filed Nov 27, 2021 02:19 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,519 | $15.04 | $67,965.76 |
DisclosureSEC source: 0001567619-21-021197 · doc1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $29.81 | $0.00 |
DisclosureSEC source: 0001567619-21-018621 · doc1.xml · derivative · entry 7 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,000 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 4, 2015, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001567619-21-018621 · doc1.xml · derivative · entry 6 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Ordinary Shares · 20,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,185 | $61.94 | $135,340.43 |
DisclosureSEC source: 0001567619-21-018621 · doc1.xml · nonDerivative · entry 5 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $61.84 to $62.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,700 | $60.91 | $103,543.94 |
DisclosureSEC source: 0001567619-21-018621 · doc1.xml · nonDerivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,185 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $60.75 to $61.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 19,115 | $60.00 | $1,146,938.23 |
DisclosureSEC source: 0001567619-21-018621 · doc1.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,885 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $59.71 to $60.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 3,000 | $29.81 | $89,430.00 |
DisclosureSEC source: 0001567619-21-018621 · doc1.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 20,000 | $15.04 | $300,800.00 |
DisclosureSEC source: 0001567619-21-018621 · doc1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 2,374 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082598 · tm2119990d2_4.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,122 Underlying: Common Stock · 2,374 shares Expires 2031-06-15 F3 · price: These options were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082598 · tm2119990d2_4.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,122 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F3 · price: These options were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082598 · tm2119990d2_4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F2 · shares: The reporting person received an award of 1,187 restricted stock units on June 15, 2021, which shall vest in three equal installments on June 15, 2022, June 15, 2023, and June 15, 2024. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082598 · tm2119990d2_4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 22:09 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $22.60 | $0.00 |
DisclosureSEC source: 0001567619-21-005080 · doc1.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Ordinary Shares · 28,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,796 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004311 · doc1.xml · derivative · entry 8 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,796 Underlying: Ordinary Shares · 18,796 shares Expires 2028-02-21 F7 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 25,000 of the issuer's ordinary shares granted to the reporting person on February 21, 2018. In exchange, the reporting person received a replacement option, for 18,796 ordinary shares, having an exercise price of $22.85 per ordinary share. F8 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 47/48 of the total number of shares subject to the option on the one year anniversary of the date of grant and with respect to 1/48 of the total number of shares subject to the option on February 21, 2022, subject to the reporting person's continued service with the issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $33.10 | Not disclosed |
DisclosureSEC source: 0001567619-21-004311 · doc1.xml · derivative · entry 7 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,000 shares Expires 2028-02-21 F7 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 25,000 of the issuer's ordinary shares granted to the reporting person on February 21, 2018. In exchange, the reporting person received a replacement option, for 18,796 ordinary shares, having an exercise price of $22.85 per ordinary share. F6 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,625 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004311 · doc1.xml · derivative · entry 6 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Ordinary Shares · 15,625 shares Expires 2027-02-22 F5 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's ordinary shares granted to the reporting person on February 22, 2017. In exchange, the reporting person received a replacement option, for 15,625 ordinary shares, having an exercise price of $22.85 per ordinary share. F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $55.00 | Not disclosed |
DisclosureSEC source: 0001567619-21-004311 · doc1.xml · derivative · entry 5 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,000 shares Expires 2027-02-22 F5 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's ordinary shares granted to the reporting person on February 22, 2017. In exchange, the reporting person received a replacement option, for 15,625 ordinary shares, having an exercise price of $22.85 per ordinary share. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 22, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,625 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004311 · doc1.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Ordinary Shares · 15,625 shares Expires 2026-02-24 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 25,000 of the issuer's ordinary shares granted to the reporting person on February 24, 2016. In exchange, the reporting person received a replacement option, for 15,625 ordinary shares, having an exercise price of $22.85 per ordinary share. F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $34.61 | Not disclosed |
DisclosureSEC source: 0001567619-21-004311 · doc1.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,000 shares Expires 2026-02-24 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 25,000 of the issuer's ordinary shares granted to the reporting person on February 24, 2016. In exchange, the reporting person received a replacement option, for 15,625 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,909 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004311 · doc1.xml · derivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,909 Underlying: Ordinary Shares · 15,909 shares Expires 2025-03-11 F2 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 17,500 of the issuer's ordinary shares granted to the reporting person on March 11, 2015. In exchange, the reporting person received a replacement option, for 15,909 ordinary shares, having an exercise price of $22.85 per ordinary share. F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 17,500 | Not disclosed Strike: $27.81 | Not disclosed |
DisclosureSEC source: 0001567619-21-004311 · doc1.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,500 shares Expires 2025-03-11 F2 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 17,500 of the issuer's ordinary shares granted to the reporting person on March 11, 2015. In exchange, the reporting person received a replacement option, for 15,909 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 13:45 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001104659-20-124026 · tm2035660d2_4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-11-09 F1 · security: These options were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:20 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001567619-20-005023 · doc1.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 40,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2021 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005424 · doc4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-18-017931 · doc4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Ordinary Shares · 110,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 21:07 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $33.10 | $0.00 |
DisclosureSEC source: 0000899243-18-005301 · doc4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2028-02-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 21:16 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option(right to buy) · Derivative | 1,500 | $0.00 Strike: $27.81 | $0.00 |
DisclosureSEC source: 0000899243-17-022968 · doc4.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 1,500 shares Expires 2025-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 11, 2016 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 21:16 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,500 | $70.00 | $105,000.00 |
DisclosureSEC source: 0000899243-17-022968 · doc4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.